Humanin and calmodulin-like skin protein (CLSP) inhibits Alzheimer disease (AD)-related neuronal cell death via the heterotrimeric humanin receptor in vitro. It has been suggested that CLSP is a central agonist of the heterotrimeric humanin receptor in vivo. To investigate the role of CLSP in the AD pathogenesis in vivo, we generated mouse CLSP-1 transgenic mice, crossed them with the APPswe/PSEN1dE9 mice, a model mouse of AD, and examined the effect of CLSP overexpression on the pathological phenotype of the AD mouse model. We found that over-expression of the mouse CLSP-1 gene attenuated spatial learning impairment, the loss of a presynaptic marker synaptophysin, and the inactivation of STAT3 in the APPswe/PSEN1dE9 mice. On the other hand, CLSP over-expression did not affect levels of Ab, soluble Ab oligomers, or gliosis. These results suggest that the CLSPmediated attenuation of memory impairment and synaptic loss occurs in an Ab-independent manner. The results of this study may serve as a hint to the better understanding of the AD pathogenesis and the development of AD therapy. Alzheimer disease (AD) is a neurodegenerative disease that is the most common cause of dementia. It is pathologically characterized by synaptic and neuronal loss, and the formation of senile plaques and neurofibrillary tangles. Humanin, a secreted 24-amino acid peptide, was originally discovered as a bioactive factor that inhibited neuronal cell death, caused by enforced expression of a London-type familial AD-linked mutant of APP in vitro (Nishimoto et al. 2004; Matsuoka 2011) . Numerous studies have shown that humanin has a variety of additional functions including inhibition of various types of cell death, metabolic, and antiinflammatory effects (Yen et al. 2013; Matsuoka 2015) . Address correspondence and reprint requests to Masaaki Matsuoka, Department of Pharmacology and Dermatological Neuroscience, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan. E-mail: sakimatu@tokyo-med.ac.jp
Alzheimer disease (AD) is a neurodegenerative disease that is the most common cause of dementia. It is pathologically characterized by synaptic and neuronal loss, and the formation of senile plaques and neurofibrillary tangles. Amyloid b precursor protein (APP), presenilin1 (PSEN1), and PSEN2 genes have been identified as familial ADcausative genes and APOE and Trem2 genes have been found as AD-risk genes (Hardy and Selkoe 2002; Selkoe 2013a) . The AD pathogenesis remains unclear (Tayeb et al. 2013; Scheltens et al. 2016 ) and disease-modifying therapy for AD is lacking (Selkoe 2013b; Scheltens et al. 2016; Selkoe and Hardy 2016) .
Humanin, a secreted 24-amino acid peptide, was originally discovered as a bioactive factor that inhibited neuronal cell death, caused by enforced expression of a London-type familial AD-linked mutant of APP in vitro (Nishimoto et al. 2004; Matsuoka 2011) . Numerous studies have shown that humanin has a variety of additional functions including inhibition of various types of cell death, metabolic, and antiinflammatory effects (Yen et al. 2013; Matsuoka 2015) .
Three humanin receptors have been identified (Matsuoka and Hashimoto 2010) . The inhibition of AD-relevant neuronal cell death by humanin is mediated by binding to the heterotrimeric humanin receptor, which is composed of ciliary neurotrophic factor receptor a (CNTFRa), WSX-1, and gp130 (Hashimoto et al. 2009; Matsuoka and Hashimoto 2010) , and by activating JAK2/STAT3 pathway (Hashimoto et al. 2005; Chiba et al. 2009 ).
We recently identified calmodulin-like skin protein (CLSP) as an alternative physiological agonist for the heterotrimeric humanin receptor . CLSP is secreted into the extracellular space. In vitro, secreted CLSP inhibits neuronal death, caused by enforced expression of V642I-APP, via the heterotrimeric humanin receptor. Importantly, CLSP has 10 5 -fold more potent neuroprotective effect against the V642I-APP-induced neuronal death than humanin and the 50% effective concentration of CLSP for the heterotrimeric humanin receptor is approximately 1-10 9 10 À10 mol/L ). Although CLSP is structurally similar to calmodulin, it has been unknown whether CLSP functions as an intracellular signaling molecule like calmodulin. CLSP is abundantly expressed in skin tissues and also weakly expressed in epithelial cells of some issues such as the thyroid, breast, prostate, and kidney while it is barely expressed in the brain (Mehul et al. 2000; Hwang et al. 2005) . It is highly likely that CLSP is efficiently transported to the central nervous system across the blood-brain barrier and the blood-cerebrospinal fluid barrier (Hashimoto et al. , 2017 . Measured concentrations of CLSP in the human cerebrospinal fluids are 3-7 9 10 À9 mol/L (Hashimoto et al. 2017) . Intraperitoneal administration of recombinant CLSP ameliorates memory impairment, caused by scopolamine, an anti-cholinergic agent (Hayashi et al. 2014) . These data strongly suggest that CLSP functions in the central nervous system. To investigate the neuroprotective effect of CLSP against AD-like pathology in vivo, we herein have generated mouse CLSP-1 transgenic mice (CLSP mice) and crossed them with APPswe/PSEN1dE9 mice (APP/PS1 mice), a murine model of AD. This study demonstrates that transgenic overexpression of CLSP inhibits the loss of a synaptic marker synaptophysin and the inactivation of STAT3 in the hippocampus and improves memory impairment in APP/ PS1 mice via an Ab-independent mechanism.
Materials and methods

Animals
This study was not pre-registered. No test for outliers was conducted on the data obtained in the study. All animal experiments were approved by the Institutional Animal Care and Use Committee of Tokyo Medical University (No. H290026) and were conducted in accordance with the Society's Policies on the Use of Animals in Neuroscience Research. Used numbers of mice and mouse ages are presented in the figure legend. For the generation of CLSP mice, a DNA fragment encoding mouse Clsp-1 (mClsp-1) [NM_020036.4 : alternative name, scarf; (Hwang and Morasso 2003) ], C-terminally tagged with a myc-His epitope, was subcloned into XhoI-NotI site of the pCAGGS vector. The original mCLSP-1 cDNA was PCR-cloned using mouse skin tissues . The 2.15 kb DNA fragment containing the CAG promoter (Miyazaki et al. 1989) , the mCLSP-1-mycHis-encoding DNA, and the b-globulin polyA tail, was excised by SpeI and HindIII digestion (Fig. 1a) . The DNA fragment was microinjected into C57BL/6J fertilized eggs that were then transferred into pseudopregnant female mice. APP/PS1 mice (B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax, Cat# 005864, RRID:MMRRC_037568-JAX) were obtained from the Jackson Laboratory (Bar Harbor, ME, USA) and crossed with CLSP mice. After weaning at 1 month of age, mice were genotyped by tail specimens and identified by ear-punched IDs. Two mice from each genotype line were arbitrarily selected and housed into a cage by descending order of ID number and totally eight mice from four genotype lines. Furthermore, mice were allocated to all experiments in descending order of ID number as well as housing. The experimenters were not blinded to the genotypes of mice which they were handling. Mice were bred and maintained at the Pre-clinical Research Center of Tokyo Medical University under specific pathogen-free conditions. They were housed in an air-conditioned room with a 12/12-h dark/light cycle.
The sample size was based on previous study (Chiba et al. 2009; Kusakari et al. 2015) and our preliminary experiments. After each experiment, the genotypes of all mice were re-checked.
Inclusion and exclusion criteria
To exclude the effect of sexual cycle on the results, only male mice were used for all experiments except for the measurement of body weights. For the inclusion/exclusion of mice for the Morris water maze test, training to escape onto the platform in the pool was performed for seven consecutive days just before the water maze test was performed. Mice that were unable to climb up to the platform or to swim were excluded from the test.
Primary antibodies and reagents
Rabbit polyclonal antibody (pAb) specific for mouse calmodulin-like skin protein-1 (CLSP-1 antibody) was generated against a synthetic peptide corresponding to amino acids 1-18 (MSHGFTKEEVAEF-QAAFN: NM_020036.4) of mouse CLSP-1 and was purified from serum using affinity column made with the synthetic peptide. Another rabbit pAb against CLSP (GST-CLSP antibody) was generated, as described previously . Mouse mAbs to PSD95 (Cat# MABN68, RRID:AB_10807979), to APP (Cat# MAB348, RRID:AB_94882), to calmodulin (Cat# 05-173, RRID: AB_309644), and rabbit pAb to calbindin D-28K (Cat# AB1778, RRID:AB_2068336) as well as a rat mAb to PS1 (Cat# MAB1563, RRID:AB_11215630) were obtained from Millipore (San Diego, CA, USA). Rabbit pAb to actin (Cat# A5060, RRID:AB_476738) was obtained from Sigma-Aldrich (St. Louis, MO, USA). A mouse mAb to GFAP (Cat# 3670, RRID:AB_561049) and a rabbit pAb to phospho-STAT3 (Cat# 9131, RRID:AB_331586) were from Cell Signaling Technology (Beverly, MA, USA). A mouse mAb to synaptophysin (Cat# D073-3, RRID:AB_592778) was from Medical & Biological Laboratories (Aichi, Japan). A rabbit pAb to Iba1 (Cat# 019-19741, RRID:AB_839504) was from Wako (Osaka, Japan). A mouse mAb to human amyloid b (clone: 82E1, Cat# 10323, RRID: AB_1630806) was from Immuno-Biological Laboratories (Gunma, Japan).
Morris water maze test
Morris water maze tests were performed as described previously with some modifications (Kusakari et al. 2015) . The sample size was determined based on previous studies (Kusakari et al. 2015) and preliminary experiments. No separate sample size calculation was performed. Before the water maze test was performed, mice were trained to escape onto the platform in the pool for seven consecutive days (14 male mice per each mouse line). Actually, all mice withstood the training. As a consequence, 14 male mice per each mouse line were able to be used for the tests. The first training session was started at the age of 12 months 26 days. The pool was 100 cm in diameter and filled with opaque water at room temperature (22°C). A platform (10 cm in diameter) was used for the hidden platform trials, and the top surface of the platform was 1 cm below the water surface. The first trial was started at AM 9:30 each day, and 4 trials per day were performed with an interval of about 30 min. For the first training session, mice were trained to find a hidden platform in the same position during four consecutive days (4 trials per day). In each training session, mice were allowed to swim until they found the platform or until 60 s had elapsed. Mice that failed to find the platform were guided to the platform and then allowed to remain there for 30 s. Twenty-four hours after the first training session, the platform was removed, and the first probe test was performed for 60 s. Twenty-four hours after the first probe test, the platform was moved to a position opposite to that in the training period, and reversal training was monitored for 3 days (4 trials per day). Then, 24 h after the reversal training session, the platform was removed, and the second probe test was performed for 60 s. Twenty-four hours after the second probe test, mice were subjected to a visible platform test for 2 days (4 trials per day). For the visible platform test, the platform was marked with a small white flag 10 cm above the surface of the water. The behavior of mice was recorded with a CCD camera, and total traveled distance, average swimming speed, escape latency to the platform, and time spent in the target quadrant were measured automatically (O'Hara & Co., Tokyo, Japan).
Immunoblot analysis
Immunoblot analysis was performed, as previously reported (Ohnishi et al. 2010) . Mice were killed by cervical dislocation, as employed in earlier studies (Kusakari et al. 2015) , and hippocampi were dissected into ice-cold phosphate-buffered saline (PBS) and homogenized at 4°C in the lysis buffer [20 mM Tris-HCl (pH 7.6), 140 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% NP-40, 1 mM phenylmethylsulfonyl fluoride, aprotinin (10 lg/mL), 1 mM sodium vanadate]. The homogenates were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblot analysis. The ratio of the amount of mClsp-1 mRNA to that of the b-actin mRNA is presented as a fold change relative to the mean value for WT mice. Scatter plot graphs show individual data. Data indicated by bars are means AE SEM of a total of 5 male mice (15-month-old). **p < 0.01 (one-way ANOVA, post hoc Dunnett). (e) Coronal hippocampal sections, prepared from WT and CLSP mice (2 month-old) were immunostained using the CLSP-1 antibody. These panels show the expression of mCLSP-1 in hippocampal CA1 regions. Scale bar, 50 lm.
Histological analysis
For histological analysis, mice were anesthetized by inhalation of isoflurane, a very common anesthetic drug, in laboratory and then perfused transcardially with PBS containing 10 unit/mL heparin sodium (Mochida pharmaceutical co., ltd., Tokyo, Japan) and then with the fixation buffer [4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4)]. Brain and skin tissues were dissected and fixed again in the fixation buffer overnight at 4°C with gentle shaking. These tissues were subsequently transferred to sucrose solution [30% (w/v) in 0.1 M phosphate buffer (pH 7.4)], embedded in OCT compound (Sakura Fine Technical, Tokyo, Japan), and rapidly frozen in liquid nitrogen. Frozen sections with a thickness of 10 lm were prepared with a cryostat, mounted on MAS-coated glass slides (Matsunami Glass Ind., Ltd., Osaka, Japan), and air-dried. For the staining using the phospho-STAT3 antibody, mice were killed by cervical dislocation and brain tissues were dissected into ice-cold PBS and embedded in the OCT compound, and rapidly frozen in liquid nitrogen. Fresh frozen sections with a thickness of 10 lm were prepared with a cryostat and then fixed with the fixation buffer. All sections were then incubated for 1 h at 22°C in blocking buffer [PBS supplemented with 5% bovine serum albumin and 0.1% Triton X-100]. They were stained overnight at 4°C with primary antibodies diluted in the blocking buffer. For staining of amyloid plaques, three sections were incubated 2 overnight at 4°C with a monoclonal antibody to Ab (82E1). They were then washed with PBS and exposed to corresponding secondary antibodies conjugated with the fluorescent dye Cy3 (Jackson Immuno Research Laboratories, West Grove, PA, USA). For Nissl staining, sections were stained with 0.1% cresyl violet acetate.
Fluorescence images were acquired using an LSM710 confocal microscope (Carl Zeiss, Oberkochen, Germany) or a Biozero BZ-8000 microscope (Keyence, Osaka, Japan), and bright field images were observed using a Biozero BZ-8000 microscope. For the evaluation of amyloid plaques, Ab-stained areas (represented by pixel numbers) in the whole hippocampi were measured using the ZEN software (Carl Zeiss), and the average areas of three nonconsecutive slices of hippocampi were calculated. For the analysis of astrocytosis, the numbers of GFAP-positive particles were quantified using ImageJ software. For the evaluation of microgliosis, Iba1-positive pixels were quantified instead of the numbers of Iba1-positive particles because multiple Iba1-positive particles sometimes merged. For the evaluation of synaptic status, PSD95-positive puncta were counted in three representative 50 9 50 lm areas in the hippocampal CA1 regions and the average number of puncta per area was calculated. Because synaptophysin-positive particles are too dense to be counted correctly, the mean fluorescence intensity of synaptophysin in a 100 9 100 lm area of the hippocampal CA1 or CA3 region was measured using the ZEN software. For the analysis of the phospho-STAT3 levels, the mean fluorescence intensity of phospho-STAT3 in 50 nuclei of the hippocampal CA3 pyramidal neurons was measured using the ZEN software.
Ab ELISA Ab extracts from mouse brain homogenates were prepared, as described previously (Casali et al. 2015) . Briefly, after mice were anesthetized, whole brain tissues were immediately dissected and rapidly frozen in liquid nitrogen. Frozen brain tissues were homogenized using a glass Teflon homogenizer in the Tissue homogenization buffer [2 mM Tris-HCl (pH 7.5), 250 mM sucrose, 0.5 mM EDTA, 0.5 mM EGTA, 1% NP-40, 1 mM phenylmethylsulfonyl fluoride, aprotinin (10 lg/mL), 1 mM sodium vanadate]. The homogenates were then extracted with the diethylamine solution [0.2% diethylamine, 0.1 M NaCl], and were centrifuged at 135 000 g for 1 h. The supernatants were collected as soluble fractions and neutralized with 0.5 M Tris-HCl (pH 6.8). The resulting pellets were resuspended in 70% formic acid containing 1 mM phenylmethylsulfonyl fluoride, aprotinin (10 lg/mL), and 1 mM sodium vanadate and sonicated on ice. The suspensions were centrifuged at 135 000 g for 1 h, and the supernatants (insoluble fractions) were neutralized with formic acid neutralization buffer [1 M Tris, 0.5 M Na 2 HPO 4 , 0.05% NaN 3 ]. ELISA analysis for soluble or insoluble Ab1-40 (Cat# 298-62301, no RRID) and Ab1-42 (Cat# 298-62401, no RRID) was performed using a human b amyloid ELISA kit (Wako).
Quantitative PCR analysis Total RNA was extracted from dissected hippocampus using Sepasol RNA I (Nacalai Tesque, Kyoto, Japan) and an RNeasy Mini kit (Qiagen, Hilden, Germany). First-strand cDNA was synthesized from 1 lg of total RNA using a QuantiTect Reverse Transcription kit (Qiagen), and cDNA fragments of interest were amplified by real-time PCR using Fast SYBR Green Master Mix and the StepOne Real-Time PCR System (Applied Biosystems, Carlsbad, CA, USA). Amplification results were analyzed using StepOne software and were then normalized to the b-actin mRNA level in each sample. Primer sequences (forward and reverse, respectively) were as follows: Clsp, 
Statistical analysis
Results
Characterization of CLSP transgenic mice
The CLSP-1 transgenic mice (CLSP mice) were viable and showed no gross abnormalities. These transgenic mice constitutively expressed mouse CLSP-1 under the Cytomegalo virus early enhancer and the chicken b-actin promoter [termed CAG promoter, (Miyazaki et al. 1989 )] (Fig. 1a) . Consistent with a previous report (Mehul et al. 2000) , endogenous CLSP expression was prominent in skin tissues of wild-type (WT) mice. The skin CLSP levels in the CLSP mice were higher than those in WT mice (Fig. 1b) . Immunoblot and real-time PCR analyses indicated that although endogenous CLSP protein and mRNA were hardly detected in the brain lysates of WT mice, ectopic CLSP protein and mRNA were detected in those of CLSP mice ( Fig. 1c and d) . Consistently, immunohistochemical staining indicated that the ectopic CLSP protein was detected in hippocampal neurons (Fig. 1e) . For the examination of the potential neuroprotective effect of CLSP in AD, CLSP mice were crossed with the APP/PS1 transgenic mice that transgenically over-express both the Swedish APP mutant and the PSEN1 mutant lacking exon 9 (Fig. 2a) to generate APP/PS1/CLSP mice. It has been reported that amyloid plaques are deposited and neuronal synaptic loss occurs in the hippocampi and cerebral cortices of the aged APP/PS1 mice (Jankowsky et al. 2004; GarciaAlloza et al. 2006) , and that both spatial learning and contextual memory are impaired in these mice (Lalonde et al. 2005; Kilgore et al. 2010; Volianskis et al. 2010 ). In the current study, the body weights of the four different mouse lines (WT, CLSP, APP/PS1, and APP/PS1/CLSP) were not different (Fig. 2b) .
It have been reported that APP/PS1 mice exhibit spontaneous epileptic seizures and some of these mice die by seizure (Minkeviciene et al. 2009 ). In the current experiment, APP/PS1 mice began to die at about 10 weeks of age (Fig. 2c) , as previously reported (Minkeviciene et al. 2009 ). Transgenic over-expression of CLSP did not suppress lethality of APP/PS1 mice caused by seizures (Fig. 2c) . These results suggest that CLSP has no effect on growth, development, or seizure in these mice. Nissl staining revealed that brain structure in CLSP, APP/PS1, and APP/ PS1/CLSP mice was normal ( Fig. 2d and e) . Interestingly, CLSP over-expression resulted in the longevity of life only in the absence of APP/PS1 over-expression (Fig. 2c) . 
CLSP attenuates spatial learning impairment
To investigate the effect of CLSP over-expression on ADrelated dementia, we performed the Morris water maze test, a hippocampus-dependent spatial learning test, based on the timeline diagram of the study (Fig. 3a) . It has been reported that spatial learning in APP/PS1 mice is impaired by aging (Lalonde et al. 2005; Volianskis et al. 2010) . For the first step of this test, male mice at 13 months of age were trained to escape onto a hidden platform. Four sessions of training were performed per day for four consecutive days. Mice learned the location of the hidden platform and the latency to escape onto the platform (escape latency) was gradually reduced by training. The escape latency in APP/PS1 mice was significantly longer than in WT mice (p = 0.0027, repeated-measure ANOVA). In comparison, the escape latency of CLSP mice was similar to that in WT mice (p = 0.6769, repeated-measure ANOVA) (Fig. 3b) . The escape latency in APP/PS1/CLSP mice appeared to be shorter than that in APP/PS1 mice and similar to that in WT and CLPS mice. However, statistical analysis did not reveal difference in the escape latency between APP/PS1 and APP/PS1/CLSP mice (p = 0.195, repeated-measure ANOVA) (Fig. 3b ). Swim speed was not different between the four groups (Fig. 3c) . In the first probe test, the time spent in the quadrant where the platform was previously located was significantly longer than the time spent in the other quadrants for each of the four groups. Unexpectedly, however, statistical analysis did not reveal difference in the time spent in the quadrant between the four mouse groups (Fig. 3d ). The reversal training was then performed as the second training session. Usually, mice with worsened memory tend to show clearer impaired memory performance in the reversal training session than in the first training session. In the second training session, the escape latency was again significantly longer in APP/PS1 mice than in WT or CLSP mice (p < 0.00001, repeated-measure ANOVA) (Fig. 3e) . Notably, the escape latency was significantly shorter in APP/PS1/CLSP mice than in APP/PS1 mice (p = 0.0007, repeated-measure ANOVA) (Fig. 3e) . Swim speed was not different between the four groups (Fig. 3f) . In the second probe test, the time spent in the target region was significantly shorter in APP/PS1 mice than in WT mice (p = 0.033, t-test), whereas it was similar in APP/PS1/CLSP and WT mice (p = 0.41, t-test) (Fig. 3g) . Performance in the visible platform test was not significantly different between the four groups (Fig. 3h) . This result indicates that all groups of mice have normal spatial recognition ability. Swim speed was nearly equal between the groups (Fig. 3i) . Taken altogether, these results indicate that the transgenic over-expression of CLSP attenuates memory impairment in APP/PS1 mice.
CLSP does not affect Ab levels
In the hippocampi and cerebral cortices of APP/PS1 mice, Ab deposits (amyloid plaques) are initially detected at around 6 months, and the number of amyloid plaques progressively increases up to 12 months (Jankowsky et al. 2004; Garcia-Alloza et al. 2006) . To examine the effect of CLSP expression on amyloid plaques, we stained amyloid plaques using a monoclonal antibody to Ab. Consistent with previous reports (Jankowsky et al. 2004; GarciaAlloza et al. 2006) , 15-month-old APP/PS1 mice showed apparent plaque deposition (Fig. 4a) . The levels of amyloid plaques were unchanged in the hippocampi of APP/PS1/ CLSP mice, compared with APP/PS1 mice, at 15 months of age (p = 0.9496, one-way ANOVA, post hoc Turkey) (Fig. 4b) .
Using ELISA, we next examined the amounts of diethylamine-soluble and insoluble Ab in whole brain. As expected, the amounts of both Ab1-40 and Ab1-42 in the diethylamine-soluble and insoluble fractions in the brains of APP/ PS1 and APP/PS1/CLSP mice were much larger than in WT and CLSP mice ( Fig. 4c and d) . Consistent with amyloid plaque result ( Fig. 4a and b) , the amounts of Abs in both the diethylamine-soluble and insoluble fractions did not differ between APP/PS1 and APP/PS1/CLSP mice (soluble Ab1-40 p = 0.9983; soluble Ab1-42 p = 0.1387; insoluble Ab1-40 p = 0.992; insoluble Ab1-42 p = 0.6646, one-way ANOVA, post hoc Turkey) ( Fig. 4c and d) . These results indicate that CLSP over-expression does not affect diethylamine-soluble or insoluble (but formic acid-soluble) Ab levels.
It has recently been suggested that soluble Ab oligomers, rather than Ab aggregates, play an important role in the AD pathogenesis, and their levels correlate with cognitive impairment in AD mouse models and human AD cases (Lesne et al. 2006; Haass and Selkoe 2007; Selkoe 2013a ). Therefore, using immunoblot analysis, we examined the effect of CLSP over-expression on the oligomerization of diethylamine-soluble Abs in the mouse brain. Ab monomer and oligomers were barely detected in both WT and CLSP mice, while markedly increased levels of soluble Ab monomer and Ab oligomers were observed in the APP/PS1 mice (Fig. 4e, lane 3-7) . Notably, a decrease in the total level or oligomerization of soluble Abs was not found in APP/PS1/CLSP mice, compared with APP/PS1 mice (Fig. 4e, lane 8-12 ).
CLSP does not suppress gliosis
In APP/PS1 mice, excessive gliosis is thought to participate in the AD pathogenesis (Dzamba et al. 2016; Yuan et al. 2016) . Therefore, we next examined the effect of CLSP expression on the gliosis in the mice by immunohistochemical analysis using antibodies to glial markers. Quantification revealed that the numbers of GFAP-positive particles and the sizes of Iba1-positive areas were markedly increased in the hippocampi of APP/PS1 mice, compared with WT mice (GFAP p = 0.0093; Iba1 p = 0.0525, one-way ANOVA, post hoc Turkey) (Fig. 5a-c) . Unexpectedly, the gliosis in APP/ PS1/CLSP mice was comparable to that in APP/PS1 mice (GFAP p = 0.991; Iba1 p = 0.8865, one-way ANOVA, post hoc Turkey) (Fig. 5a-c) .
Microglia has been reported to produce several cytokines and exerts toxic and protective effects (Wang et al. 2015; Chen and Trapp 2016) . To examine the effect of CLSP expression on microglial function, we measured mRNA levels of both pro-inflammatory and anti-inflammatory cytokines in the hippocampus using quantitative PCR analysis. Expression levels of Tnfa, Il-6, and Il-4 tended to be higher in APP/PS1 mice than in WT mice (Il-6 p = 0.1293; Tnfa p = 0.0883; Il-4 p = 0.0826, one-way ANOVA, post hoc Turkey), whereas expression levels of Il-1b were similar in APP/PS1 and WT mice (p = 0.8248, oneway ANOVA, post hoc Turkey) (Fig. 5d) . Also, expression levels of C1qa, a complement generated by microglia, was significantly higher in APP/PS1 mice than in WT mice (p = 0.0025, one-way ANOVA, post hoc Turkey) (Fig. 5d) . In comparison, expression levels of these five genes were similar in APP/PS1/CLSP and APP/PS1 mice (Il-1b p = 0.9858; Il-6 p = 0.3997; Tnfa p = 0.8467; Il-4 p = 0.7817; C1qa p = 0.2211, one-way ANOVA, post hoc Turkey) (Fig. 5d) . These results suggest that glial function is unaffected by CLSP over-expression.
CLSP ameliorates the loss of a synaptic marker synaptophysin Neuronal synaptic loss has been reported to be characteristic in AD. The correlation between cognitive decline and synaptic loss is greater than that between cognitive decline and any other AD pathological marker such as the number of amyloid plaques or the magnitude of neurofibrillary tangle formation (DeKosky and Scheff 1990; Terry et al. 1991) . In APP/PS1 mice, both synaptic loss and amyloid plaques are present (Jankowsky et al. 2004; Lalonde et al. 2005; GarciaAlloza et al. 2006; Kilgore et al. 2010; Volianskis et al. 2010) , whereas both neuronal loss and the formation of neurofibrillary tangles are nearly absent (Drummond and Wisniewski 2017) . Therefore, we next examined the status of synapses in the hippocampi of the brains of APP/PS1/ CLSP mice, compared with that of APP/PS1 mice by performing immunohistochemistry using antibodies to postsynaptic and presynaptic markers. Consistent with a previous report (Hong et al. 2016) , both the number of PSD95-positive puncta in postsynaptic neurons in the CA1 region and the fluorescence intensity of synaptophysin, a presynaptic marker, in the CA1 and CA3 regions were significantly reduced in APP/PS1 mice, compared with those in WT mice at 15 months of age (PSD95 p = 0.0002; CA1 synaptophysin p = 0.0095; CA3 synaptophysin p = 0.003, one-way ANOVA, post hoc Dunnett) (Fig. 6a-c) . This result confirms that loss of synaptic markers does occur in APP/ PS1 mice. Importantly, loss of synaptophysin was alleviated in the hippocampi of APP/PS1/CLSP mice, compared with those in APP/PS1 mice at 15 months of age (PSD95 p = 0.1683; CA1 synaptophysin p = 0.0861; CA3 synaptophysin p = 0.0294, one-way ANOVA, post hoc Dunnett) (Fig. 6a-c) .
CLSP attenuates the down-regulation in phosho-STAT3 levels in hippocampal neurons of APP/PS1 mice Consistent with the result in a previous study (Chiba et al. 2009 ), immunohistochemical analysis indicated that the levels of phospho-STAT3, an activated form of STAT3, were down-regulated in hippocampal neurons of APP/PS1 mice at 4 months of age, compared with WT and CLSP mice (p < 0.0001, one-way ANOVA, post hoc Turkey) ( Fig. 7a and  b) . In vitro, CLSP activates a JAK2/STAT3 pathway via the heterotrimeric humanin receptor and induces gene expression related to neuroprotection Takeshita et al. 2013; Matsuoka 2015) . In the presence of CLSP overexpression, the down-regulation of the phospho-STAT3 levels was significantly attenuated (P = 0.0214, one-way ANOVA, post hoc Turkey) ( Fig. 7a and b) . CLSP inhibits the down-regulation in mRNA expression of Arc, an immediate early gene We next examined the expression of some immediate early genes that may prevent synaptic loss or promote synapse formation in APP/PS1 mice. The expression of Arc was significantly lower in APP/PS1 mice than in WT mice (p = 0.0092, one-way ANOVA, post hoc Turkey). The expression of Arc was up-regulated in APP/PS1/CLSP mice, compared with that in APP/PS1 mice (p = 0.0271, one-way ANOVA, post hoc Turkey) (Fig. 8) . The expression of other immediate early genes, bdnf and c-fos, did not show the significant decrease in APP/PS1 mice (Fig. 8) .
Discussion
Currently available AD model mice including APP/PS1 mice, used in the present study, mimic amyloid plaques and synaptic loss, two characteristic pathological features of AD.
On the other hand, most AD model mice do not exhibit the two other major AD pathological phenotypes, i.e. the formation of neurofibrillary tangles and neuronal loss that is almost equivalent to neurodegeneration (Drummond and Wisniewski 2017) , although neuronal loss can be observed in some AD transgenic mice, usually at very advanced ages. In reality, only the effect of CLSP on amyloid plaques, neuronal synaptic loss, and memory impairment could be examined using APP/PS1 mice in this study. We have herein shown that transgenic over-expression of CLSP alleviates memory impairment and the loss of synaptophysin in aged APP/PS1 mice. This result suggests that CLSP is neuroprotective against AD in vivo. Originally, CLSP was discovered as an alternative agonist of the heterotrimeric humanin receptor (Matsuoka 2015) . Because humanin transgenic animals have not been generated, the present study shows, for the first time, that transgenic activation of the heterotrimeric humanin receptor may ameliorate synaptic loss, the important pathological feature of AD.
In the first training session of the Morris water maze test, the escape latency in APP/PS1 mice was significantly longer than in WT mice (Fig. 3a) . However, statistical analysis did not reveal difference in the escape latency between APP/PS1 and APP/PS1/CLSP mice although the escape latency in APP/PS1/CLSP mice appeared to be shorter than that in APP/PS1 mice and similar to that in WT and CLPS mice (Fig. 3a) . It is highly likely that increase in the number of tested mice may lead to a statistically significant difference. Also, in the first probe test, statistical analysis was unable to reveal difference in the time spent in the quadrant between the four mouse groups (Fig. 3c) . Generally, the memory performance test in the first training session and the first probe test are less capable of detecting the memory impairment than that in the second training session (the reversal training) and the second probe test. It is likely that the condition particularly employed in the current Morris water maze test may further reduce the ability of detecting memory impairment. In reality, using the reversal training session that may serve a more sensitive test than the first training session, we could demonstrate that APP/PS1 mice have worsened memory acquisition and APP/PS1/CLSP mice show the statistical significant improvement in memory acquisition, compared with APP/PS1 mice (Fig. 3d) . In the second probe test, the time spent in the target region was significantly shorter in APP/PS1 mice than in WT mice, whereas it was similar in APP/PS1/CLSP and WT mice.
The transgenic over-expression of CLSP did not inhibit the formation of amyloid plaques in the present study ( Fig. 4a  and b) . Consistently, it did not significantly impact the diethylamine-insoluble (and formic acid-soluble) or diethylamine-soluble Ab levels ( Fig. 4c-e) . In contrast to the result in the current study, previous studies have shown that peripheral administration of humanin analogues lowers the levels of soluble and insoluble Ab in some AD model mice that transgenically over-expressing familial AD-linked genes (Niikura et al. 2011; Zhang et al. 2012; Yin et al. 2016) . Three possible reasons could be considered for this discrepancy. First, CLSP may lack the Ab-lowering function that humanin possesses, which therefore might be independent on the heterotrimeric humanin receptor. Indeed, in a previous study (Niikura et al. 2011) , the administration of a humanin analogue peptide up-regulated the level of neprilysin, an Abdegrading enzyme, in some regions of the mouse brains. CLSP may not have this function. Second, a difference in the periods when the mice were exposed to the neuroprotective peptides may account for the contrasting results. CLSP was continuously present in the CLSP transgenic mice since development, whereas the humanin analogues were administered for defined periods during the adulthood in the other studies. Third, differences in the level of humanin or CLSP may underlie the discrepancy. The levels of CLSP overexpression appeared to be small in the current study (Fig. 1) , whereas peripheral administration of a large amount of a humanin analogue may result in extremely high levels in the mouse brain.
Synaptic loss occurs in AD model mice, including APP/ PS1 mice, and human AD cases, and is thought to correlate with cognitive decline (Terry et al. 1991) . It is highly likely that synaptic loss ultimately leads to neuronal loss in AD. Although the mechanism underlying the synaptic loss in AD still remains unclear, the prevalent hypothesis is that increased levels of Ab bind to neurons and directly causes synaptic loss (Hardy and Selkoe 2002 ). An alternative hypothesis is that increased Ab induces chronic inflammation including astrocytosis and microgliosis (Calsolaro and Edison 2016 ) that eventually cause synaptic loss. Both mechanisms may underlie synaptic loss co-operatively. Indeed, the activation of microglia has been suggested to play a key role in the AD pathogenesis (Wang et al. 2015; Chen and Trapp 2016; Hong et al. 2016; Yuan et al. 2016) . It has been reported that activated microglia phagocytose synapses via the complement pathway, and that the facilitation of pruning by microglia causes synaptic loss and cognitive deficits (Hong et al. 2016) . In the present study, however, CLSP over-expression did not affect gliosis or gliamediated cytokine production in APP/PS1 mice (Fig. 5) . Furthermore, C1qa, the initial protein of the classical complement cascade, was expressed at similar levels in both APP/PS1/CLSP and APP/PS1 mice (Fig. 5d) . These results , and APP/ PS1/CLSP mice (15-month-old), were immunostained with the monoclonal antibodies to PSD95, a postsynaptic marker (upper panels) and to synaptophysin, a presynaptic marker (lower panels). Scale bars, 10 lm. (b) PSD95-positive puncta were counted in three 50 9 50 lm areas of the hippocampal CA1 regions, and the average number of PSD95-positive puncta per area was calculated. Scatter plot graphs show individual data. Data indicated by bars are means AE SEM of a total of 7 male mice (15-month-old). **p < 0.01, *p < 0.05 (one-way ANOVA, post hoc Dunnett). (c) The mean fluorescence intensity of synaptophysin (Syn) in the 100 9 100 lm areas of the hippocampal CA1 or CA3 regions was measured using the ZEN software, and is presented as a fold change relative to the mean value for WT mice. Scatter plot graphs show individual data. Data indicated by bars are means AE SEM of a total of 7 male mice (15-month-old). **p < 0.01, *p < 0.05 (one-way ANOVA, post hoc Dunnett). NS: Not significant. (d) Total RNA was extracted from the hippocampal samples from WT, CLSP, APP/PS1, and APP/PS1/CLSP mice. The expression levels of cytokines, Il-1b, Il-6, Tnfa, and Il-4, and the complement factor C1qa, were determined using quantitative PCR. The ratio of the amount of mRNA of each gene to that of the b-actin is presented as a fold change relative to the mean value for WT mice, and scatter plot graphs show individual data. Data indicated by bars are means AE SEM of a total of 5 male mice (15-month-old). *p < 0.05, **p < 0.01 (one-way ANOVA, post hoc Turkey).
suggest that the CLSP-mediated attenuation of synaptic loss is not mediated by the inhibition of gliosis.
The modified amyloid b cascade hypothesis, supported by numerous recent studies, suggests that soluble Ab oligomers, rather than aggregated Ab, play a major role in Ab toxicity in AD (Haass and Selkoe 2007; Selkoe 2013a ). In the current study, however, CLSP over-expression did not affect the levels of soluble Ab oligomers or decreased the number of amyloid plaques (Fig. 4) . This finding indicates that the CLSP-induced suppression of synaptic loss is not mediated by a reduction in the levels of soluble Ab oligomers or Ab plaques. Total RNA was extracted from the hippocampal samples of wild-type (WT), CLSP, APP/PS1, and APP/PS1/CLSP mice. The expression levels of Bdnf, c-fos, and Arc genes were determined using the quantitative PCR. The ratio of the amount of mRNA for each immediate early gene to that of the b-actin is presented as a fold change relative to the mean value for WT mice. Scatter plot graphs show individual data. Data indicated by bars are means AE SEM of a total of 5 male mice (15-month-old). *p < 0.05, **p < 0.01 (one-way ANOVA, post hoc Dunnett).
A previous study (Chiba et al. 2009 ) demonstrated that the phospho-STAT3 levels are down-regulated in an agedependent manner in hippocampal neurons of many AD model mice that transgenically over-express familial ADcausative genes. Consistently, the phospho-STAT3 levels were down-regulated in hippocampal neurons of aged APP/ PS1 mice in the current study (Fig. 7) . It was also shown that CLSP activates a JAK2/STAT3-mediated pro-survival signaling pathway in neurons via the heterotrimeric humanin receptor Matsuoka 2015) . As expected, in the current study, CLSP over-expression attenuated the down-regulation in the phospho-STAT3 levels in hippocampal neurons of aged APP/PS1 mice (Fig. 7) . These data support the idea that CLSP inhibited synaptic loss and memory impairment of APP/PS1 mice at least partially by activating JAK2/STAT3-mediated pro-survival signaling pathway in hippocampal neurons. We also found that the single over-expression of CLSP did not increase the phospho-STAT3 levels, as compared with WT mice (Fig. 7) . Regarding this finding, we assume that the activation of the heterotrimeric humanin receptor was saturated by endogenous CLSP in WT mice. This assumption needs to be investigated in the future investigation.
Activated STAT3 alters transcription of a variety of genes. In vitro, it results in the inhibition of AD-related neuronal cell death mainly via the induction of SH3BP5 expression (Takeshita et al. 2013) . This pathway may play a key role in protecting against synaptic loss by regulating the transcription of many genes in the currently used mice. Expression of immediate early genes has been known to be induced by neuronal excitation and used as an index of neuronal activity (Greer and Greenberg 2008; Lyons and West 2011) . Among others, Arc expression is important for circuit re-organization and synaptic plasticity (Minatohara et al. 2015) . The expression levels of Arc which was down-regulated in APP/PS1 mice, returned to the normal level in APP/PS1/ CLSP mice (Fig. 8) .
Recently, it was reported that the activation of the JAK/ STAT3 pathway promotes synapse formation and axon outgrowth in the injured brain (Hoffmann et al. 2015; ). In the current study, however, synapse formation was not facilitated by CLSP over-expression in CLSP mice (Fig. 7) . Therefore, CLSP may induce these genes expression via the activation of the JAK/STAT3 pathway and promote or sustain synapse formation only in response to damage to neurons.
The dysregulation of intracellular calcium, calmodulin, and calcium-binding molecules including some Ca 2+ / calmodulin-binding proteins may contribute to the AD pathogenesis (the calcium hypothesis) (O'Day et al. 2015) . Based on the finding that CLSP is structurally similar to calmodulin and a Ca 2+ -binding protein (Mehul et al. 2000; Hwang et al. 2005) , and CLSP may interacts with several intracellular proteins including 14-3-3 proteins, calreticulin, and annexin proteins (Hwang et al. 2007) , it could be also hypothesized in the current study that neuronal expression of CLSP contribute to the amelioration of synaptic loss by affecting some neuronal calcium signalings. However, there is no evidence indicating that CLSP functions like calmodulin in calcium signaling. The binding partners do not seem to be common between CLSP and calmodulin (Hwang et al. 2007 ). In the current study, we found that ectopic expression of CLSP did not affect the expression of calmodulin and calbindin, another calcium-binding protein, in the mouse brain in the presence of APP/PS1 over-expression (Fig. S1) .
CLSP mRNA and proteins are scarcely produced in the brains (Hwang and Morasso 2003; Hwang et al. 2005) . Therefore, the majority of CLSP in the brain is assumed to be transported from the peripheral tissues across the blood-brain and the blood-cerebrospinal fluid barriers (Hashimoto et al. , 2017 . Given that the concentration of CLSP in the human cerebrospinal fluids exceeds the level of the effective concentration of CLSP, it is likely that the CLSP concentration in the brain parenchyma also exceed it. If this assumption is true, CLSP is thought to physiologically exert the neuroprotective effect in the human brain. However, the fine regulation of CLSP in the physiological as well as the pathological conditions remains to be investigated, especially in terms of the AD pathogenesis.
Interestingly, CLSP over-expression increased the longevity of mouse life only in the absence of the over-expression of APP/PS1. Aggressiveness was not apparently increased in CLSP mice, as suggested by the same swim speed in the Morris water maze test (Fig. 3f) . The underlying mechanism should be addressed in the future investigation.
In summary, our findings indicate that transgenic overexpression of CLSP prevents memory impairment and synaptic marker loss in an AD model mice in vivo. The neuroprotective effects of CLSP are not associated with the down-regulation of Ab levels or the attenuation of gliosis. The results of this study may serve as a hint to the better understanding of the AD pathogenesis and the development of AD therapy.
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